Allergan Inc. (AGN) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox

  To: MEDICAL EDITORS Contact: Ben Cooke, Vice President of AHPR, Inc., +1-310-398- 8680, ben@arlenehowardpr.com, for Arnold William Klein MD BEVERLY HILLS, Calif., March 6 /PRNewswire/ -- World-renowned dermatologist, Dr. Arnold Klein, is on a mission to inform the public about the dangers surrounding one of the most popular injectable...

  Research articles 2008-03-06

  Tags: Allergan Inc., Botox, dilution, Dr., Government, Klein, University of California at Los Angeles

• Allergan Comments on the United States Department of Justice Subpoena for the Production of Documents Relating to Promotional Practices of BOTOX® for Therapeutic Uses

  IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that it received a subpoena from the United States Department of Justice, United States Attorney's Office for the Northern District of Georgia requesting the production of documents regarding promotional practices involving BOTOX([R]) botulinum toxin type A for therapeutic indications.

  Research articles 2008-03-04

  Tags: Allergan Inc., Botox, U.S. Department of Justice

• Commenting on the U.S. Food and Drug Administration Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX®, Rather Than BOTOX® Cosmetic for Aesthetic Use

  IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today commented on and provided support for the U.S. Food and Drug Administration's FDA "Early Communication" regarding a safety review of botulinum toxins in the United States.

  Research articles 2008-02-08

  Tags: Allergan Inc., Botox, FDA

• Allergan, Inc. Responds to Public Citizen's Allegation Regarding a Fatality Following BOTOX® Cosmetic Treatment

  Allergan Confirms Fatality Not Caused By BOTOX([R]) Cosmetic

  Research articles 2008-01-25

  Tags: Allergan Inc., Botox, fatality

• Beyond Botox: Allergan Working Pipeline

  Concerns about eventual competition for Allergan Inc.'s cash cow Botox don't seem to be weighing on the Irvine drug maker's shares.

  Research articles 2005-10-10

  Tags: Allergan Inc., Botox

• Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate BOTOX® Development and Commercialization in Japan and China, Co-Promote IMITREX STATdose System® and AMERGE® in U.S

  IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) announced today that it has entered into a long-term agreement with GlaxoSmithKline (NYSE:GSK) to develop and promote Allergan's BOTOXR botulinum toxin type A in Japan and China and to co-promote GSK's products IMITREX STATdose SystemR sumatriptan succinate and AMERGER naratriptan hydrochloride in the United...

  Research articles 2005-10-03

  Tags: agreement, Allergan Inc., BOTOX, GlaxoSmithKline Plc.

• Artes Medical Appoints Adelbert L. Stagg, Ph.D. as VP, Regulatory Affairs and Quality Assurance; Former Allergan Regulatory Affairs Leader to Manage FDA Approval of Company Products

  SAN DIEGO -- Artes Medical Inc., a privately-held specialty pharmaceutical and medical device company, today announced the hire of Adelbert L. Stagg, Ph.D., as Vice President, Regulatory Affairs and Quality Assurance. Dr. Stagg, who was formerly part of the regulatory leadership at Allergan responsible for managing BOTOXR and BOTOXR Cosmetic...

  Research articles 2005-03-16

  Tags: Allergan Inc., Botox, FDA, leader, QA

• Allergan's Lab Guy: Eyeing New Botox Uses, Drugs

  Scott Whitcup is looking to mine Botox.

  Research articles 2005-01-10

  Tags: Allergan Inc., Botox

• Snell & Wilmer Product Liability Group Successfully Defends Allergan, Inc. in Botox Lawsuit

  IRVINE, Calif. -- Snell & Wilmer Product Liability Litigation Partners Hoot Gibson and Ellen Darling led the successful defense of Allergan, Inc. (NYSE:AGN) in the Irena Medavoy vs. Arnold Klein, M.D. and Allergan, Inc. trial which concluded October 8, 2004, in the Los Angeles County Superior Court. This was the...

  Research articles 2004-10-14

  Tags: Allergan Inc., BOTOX

• FDA Approves BOTOX — Botulinum Toxin Type A — for Treatment of Severe Underarm Sweating; New Approval Marks Fourth Therapeutic Indication for Allergan's BOTOX Over Last 15 Years

  IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration FDA approved BOTOXR botulinum toxin type A for the treatment of severe primary axillary hyperhidrosis severe underarm sweating that is inadequately managed with topical agents. Primary axillary hyperhidrosis often goes undiagnosed, misdiagnosed and untreated...

  Research articles 2004-07-20

  Tags: Allergan Inc., Botox, FDA

• Allergan brings Botox pro ads to Pacific

  ALLERGAN HAS moved the professional advertising account for Botox from Grey Healthcare Group, its agency of four years, to its own healthcare agency, Pacific Communications, as it seeks to expand therapeutic use of the treatment. The account was awarded without a formal pitch.

  Research articles 2004-06-01

  Tags: advertisement, Allergan Inc., Botox

• Allergan to Vigorously Defend Frivolous Lawsuit Against BOTOX; Stands Behind Established 20-Year Safety Profile of BOTOX

  Business Editors & Health/Medical Writers

  Research articles 2003-02-04

  Tags: Allergan Inc., Botox

• FDA approves Botox for cosmetic procedures

  Baltimore cosmetic surgeons are anticipating one of their most popular procedures will generate even more revenue with yesterday's approval of Botox by the U.S. Food & Drug Administration. The drug, a purified strain of botulinum toxin, for years has been used cosmetically to reduce lines and wrinkles, though its...

  Research articles 2002-04-16

  Tags: Allergan Inc., Botox, FDA, patient

• The lawrence summers memorial award (*).(Botox)(Brief Article)

  THE MARCH 2002 LAWRENCE SUMMERS MEMORIAL AWARD (*) goes to Allergan, Inc. of Irvine, California for its injectable drug known as Botox. About Botox, the New York Times reported in February 2002: "Without a peep of promotion, it has become the most popular ...

  Research articles 2002-03-01

  Tags: Allergan Inc., Botox, FDA, Government, muscle, New York Times Co.

Additional Resources

• Spectrum Pharmaceuticals Announces Third Quarter Corporate Update and Pipeline Review

  * Approximately $90 Million in Cash and Equivalents as of November 6, 2008 * Signed Collaboration Agreement With Allergan, Inc. for Apaziquone (EOquin([R])) on October 28, 2008 * FUSILEV[TM] Supplemental NDA for Colorectal Cancer Filed October 30, 2008 * Received Unique, Product-Specific J-Code for...

  Articles 2008-11-07

• Spectrum Pharmaceuticals Announces Receipt of $41.5 Million from Allergan, Inc. Per Collaboration Agreement for Apaziquone Announced on October 29th

  * Spectrum Will Receive Up To An Additional $304 Million Based On Achievement Of Certain Clinical, Regulatory And Commercialization Milestones * Spectrum Will Continue to Conduct Clinical Trials * Allergan to Fund 65% of Costs Starting January 1, 2009 IRVINE, Calif. -- Spectrum Pharmaceuticals,...

  Articles 2008-11-06

• Zacks Analyst Blog Highlights: Cabela's Inc., Sanmina-SCI Corp., Dollar Financial Corp., Inspire Pharmaceuticals, Inc. and Allergan, Inc

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cabela's Inc. (NYSE: CAB), Sanmina-SCI Corp. (Nasdaq: SANM), Dollar Financial Corp....

  Articles 2008-11-05

• Polyphor to Enter into an Exclusive Agreement with Allergan for the Development of Protein Epitope Mimetics Inhibitors for Ophthalmology

  Novel Cytokine Inhibitors to Treat Conditions and Diseases Affecting the Eye ALLSCHWIL, Switzerland -- Polyphor Ltd today announced that it has entered into an exclusive worldwide discovery and license agreement with Allergan, Inc., under which Allergan obtains the rights to develop PEM cytokine inhibitors for the treatment of...

  Articles 2008-10-31

• Allergan Reports Third Quarter 2008 Operating Results

  * Board of Directors Declares Third Quarter Dividend IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today announced operating results for the quarter ended September 30, 2008. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on December 1, 2008...

  Articles 2008-10-29

• Allergan, Inc. and Spectrum Pharmaceuticals, Inc. Announce Collaboration Agreement for Apaziquone

  * Apaziquone is Currently Being Investigated for the Treatment of Non-Muscle Invasive Bladder Cancer * Spectrum to Receive $41.5 Million at Closing and up to $304 Million in Milestone Payments * Spectrum to Share Profits and Expenses Equally in the United States and Receive Royalties on...

  Articles 2008-10-29